On December 2, it was reported that Sonnet BioTherapeutics received shareholder approval for a merger with Hyperliquid Strategies, Inc. This merger will allow Sonnet to change its name and manage substantial assets, including 12.6 million HYPE tokens and 300 million USD in liquid cash.
Leave a Reply